<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998579</url>
  </required_header>
  <id_info>
    <org_study_id>2012/2214-31/4</org_study_id>
    <nct_id>NCT03998579</nct_id>
  </id_info>
  <brief_title>Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer</brief_title>
  <acronym>CanMoRe</acronym>
  <official_title>The Effect of Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer - the CanMoRe Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the CanMoRe study is to evaluate the impact of a standardized and
      individually adapted exercise intervention in Primary Health Care aiming at improving
      physical function (primary outcome) and habitual physical activity, health related quality of
      life, fatigue and psychological well-being in patients undergoing radical cystectomy due to
      urinary bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common treatment for solid cancer tumours is surgery, often in combination with
      chemo- and/or radiotherapy. To minimise the postoperative complications is important in
      today's health care. Early mobilisation at the ward and physical activity at home after
      discharge, have been shown to be important parts to reduce complications. Common
      complications after abdominal surgery are postoperative pulmonary complications and venous
      thrombosis. One of the conditions that suffers the most from different kinds of postoperative
      complications is radical cystectomy due to urinary bladder cancer. Complications after
      radical cystectomy could be direct related to the patients' high age and also high degree of
      comorbidity.

      There is today strong evidence that physical activity has a positive impact on health,
      survival and quality of life. Patients who have been treated for urinary bladder cancer are
      not sufficiently physical active and suffer from readmissions to hospital due to
      complications. Therefore, there is a need for developing and testing a physical
      rehabilitation programme to support patients who have a radical cystectomy, in the early
      postoperative period.

      The CanMoRe study is a randomized controlled trial with a single-blinded design evaluating an
      exercise intervention in Primary Health Care as part of the CanMoRe programme. In addition, a
      qualitative study (interviews) on patient's experience of the programme will be conducted as
      well as data gathered on factors that might influence the implementation of the programme.

      Then CanMoRe programme consists of preoperative information, the Activity Board used for
      enhanced mobilization during hospital stay, a 12-week, (1 h, 2 times/week) standardized and
      individually adapted exercise intervention in Primary Health Care and behavioral support for
      daily physical activity. The CanMoRe programme is evaluated in two steps, i.e. the
      in-hospital intervention using the Activity Board (published) and the exercise intervention
      in Primary Health Care reported herein.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>Change from baseline to after 12 weeks intervention</time_frame>
    <description>The test reproduces activity of daily living at a sub maximal level. Output: meters Score: 0-900.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ActivPAL accelerometer</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Habitual physical activity, measured for 7 consecutive days. Output: number of steps per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chair stand test</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Measure of leg strength. Output: Scale 0-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand grip strength</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge,</time_frame>
    <description>Measure of hand grip strength (Jamar hand dynamometer). Output: Kilo 0-60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer (EORTC) Quality of life for cancer patients QLQ-C30</measure>
    <time_frame>Measurement 1: Baseline Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Health related quality of life. Output: Scale 0-100. A higher score is worse outcome. For more information see https://qol.eortc.org/questionnaires/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-BLM30</measure>
    <time_frame>Measurement 1: Baseline Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Health related quality of life specific for bladder cancer Output: Scale 0-100, a higher score is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Piper Fatigue Scale</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Fatigue. Output: Scale 0-10. A higher score is worse, i.e more fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS)</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge</time_frame>
    <description>Pain. Output: Scale 0-10, A higher score is worse i.e more pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Measurement 1: Baseline, Measurement 2: 12 weeks. Measurement 3: 1 year after discharge</time_frame>
    <description>Psychological wellbeing. Output: Scale 0-21. A higher score is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>Collected from journals using standardized time frames at 30 and 90 days</time_frame>
    <description>Readmissions to hospital. Output: Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Collected from journals using standardized time frames at 30 and 90 days</time_frame>
    <description>Complications such as Pneumonia Output: according to Clavien - Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>Measurement 3: 1 year after discharge</time_frame>
    <description>The test reproduces activity of daily living at a sub maximal level. Output: meters Score: 0-900.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Urinary Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Individualized exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The CanMoRe programme</intervention_name>
    <description>An exercise intervention in Primary Health Care</description>
    <arm_group_label>Individualized exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home exercise</intervention_name>
    <description>An active control group</description>
    <arm_group_label>Active control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are planned for a robotic assisted laparoscopic radical cystectomy due to
             urinary bladder cancer at the Karolinska University Hospital Solna will be included in
             the trial. The patients should be able to talk and understand Swedish, live in the
             Stockholm County Council area and be mobile with or without walking aid.

        Exclusion Criteria:

          -  Patients who will undergo radical cystectomy on a non-curative basis will not be
             included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Hagstromer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Porserud, MSc</last_name>
    <phone>+46736839140</phone>
    <email>andrea.porserud@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Aly, PhD</last_name>
    <phone>+4685177000</phone>
    <email>markus.aly@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Porserud, MSc</last_name>
      <phone>+46736839140</phone>
      <email>andrea.porserud@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Patrik Karlsson, MSc</last_name>
      <phone>+46739655642</phone>
      <email>patrik.karlsson@ki.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://ki.se/en/nvs/the-abdmore-project-2016-2020</url>
    <description>The link to the larger project to which this RCT belong</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Maria Hagstr√∂mer</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

